Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study

• Główni autorzy: Yu Du (Autor), Zhonghui Qi (Autor), Xianbin Liang (Autor), Jie Dai (Autor), Xiaoting Wei (Autor), Xue Bai (Autor), Lili Mao (Autor), Zhihong Chi (Autor), Chuanliang Cui (Autor), Bin Lian (Autor), Bixia Tang (Autor), Xuan Wang (Autor), Yu Chen (Autor), Jun Guo (Autor), Lu Si (Autor)
• Format: Książka
• Wydane: Mattioli1885, 2024-01-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Introduction: Pembrolizumab is well-tolerated in pediatric patients with advanced tumors, consistent with results in adults. However, information on the safety and efficacy of adjuvant pembrolizumab in children and adolescents with melanoma is lacking. Objectives: To compare pembrolizumab versus hig...